Good Vs. Right Money: Choosing Optimal Financing Avenues For Biotech

Is all capital welcome? Investor attributes matter when raising capital and different attributes matter at different times in the life of a company, says a panel of investors and biotech leaders.

Access to capital is often a great limiter for biotechs. When money does become available, it’s nearly impossible to pass it up. But especially in current times with capital being relatively more accessible, companies must proceed cautiously when considering what potential investors and other capital sources bring to the table. In times of crisis, having the right money invested in a company can make all the difference for continuing survival and return to growth.

A panel session at the Therapeutic Area Partnerships Meeting in Boston late last year considered the issues that face biotech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.